CVS Caremark Corporation - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for CVS Caremark Corporation for the thirteen-week period ended March 29, 2008. The Company operates as a fully integrated pharmacy services provider with two primary segments: Retail Pharmacy (6,267 stores) and Pharmacy Services (PBM, mail order, and specialty pharmacy). The reporting period includes the full impact of the Caremark Rx merger completed in March 2007, whereas the prior year period included only 10 days of post-merger operations.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Revenues | $21,326.0 million | $13,188.6 million |
| Gross Profit | $4,293.0 million | $3,303.2 million |
| Operating Profit | $1,370.1 million | $736.5 million |
| Net Earnings | $748.5 million | $408.9 million |
| Diluted EPS | $0.51 | $0.43 |
| Operating Cash Flow | $740.8 million | $707.7 million |
| Cash & Equivalents | $818.2 million | $710.7 million |
| Total Debt (Short + Long Term) | $9,738.2 million | $10,457.9 million |
Note: Debt figures derived from Balance Sheet (Short-term debt + Current portion of LT debt + Long-term debt).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $8.1 billion (61.7%), primarily driven by the inclusion of 91 days of Caremark operations in 2008 compared to only 10 days in 2007. Pharmacy Services revenue specifically increased by $7.9 billion.
- Profitability: Net earnings increased 83.1% to $748.5 million. Operating profit rose 86.0% to $1.37 billion. Gross profit margins improved in the Retail Pharmacy segment (29.6% vs 27.6%) due to higher generic dispensing rates and purchasing synergies.
- Interest Expense: Net interest expense more than doubled to $130.9 million from $63.9 million, attributed to higher average debt balances used to fund the Caremark merger special dividend and share repurchase programs.
- Segment Performance:
- Retail Pharmacy: Net revenue up 5.4%; Same-store revenue up 3.9%. Generic dispensing rate increased to 66.6%.
- Pharmacy Services: Net revenue up significantly due to merger inclusion. Comparable operating profit increased to $540.4 million (5.0% margin) from $506.1 million (4.8% margin).
Outlook, Risks, and Unusual Items
- Share Repurchases: The Company completed a $2.3 billion Accelerated Share Repurchase (ASR) agreement in March 2008, receiving an additional 5.7 million shares. The $5.0 billion repurchase program authorized in May 2007 was completed.
- Legal Settlements: The Company settled a government investigation regarding generic drug dispensing practices (ranitidine) for $36.7 million plus fees, entering a Corporate Integrity Agreement. The Company denied wrongdoing.
- Legal Proceedings:
- OIG Subpoena: Received a subpoena regarding Medicaid claims processing on the AdvancePCS platform; cooperating with DOJ and OIG.
- Class Actions: Facing a putative class action in Alabama seeking ~$3.2 billion regarding insurance coverage misrepresentation (Lauriello case) and employment litigation in California regarding pharmacist overtime/meal breaks.
- Operational Risks: Management highlights risks related to third-party payors reducing reimbursement rates, particularly for generic drugs, and the potential impact of the Deficit Reduction Act (DRA) on Medicaid reimbursement, though implementation has been enjoined.
- Guidance: The Company plans to open 200-225 new or relocated retail pharmacy stores for the remainder of 2008.
Investor Verification Checklist
- Merger Integration: Verify the realization of projected purchasing synergies and cost savings from the Caremark merger in subsequent quarters.
- Reimbursement Trends: Monitor the impact of increasing generic dispensing rates on reimbursement rates from third-party payors and Medicaid.
- Legal Exposure: Track the status of the OIG investigation into AdvancePCS and the $3.2 billion Alabama class action lawsuit.
- Debt Servicing: Assess the impact of elevated interest expenses on future earnings as the Company maintains a significant debt load ($9.7 billion).
- Store Economics: Evaluate the performance of new store openings and relocations against the target of 200-225 units for the year.